{"id":26565,"date":"2022-10-26T10:20:13","date_gmt":"2022-10-26T09:20:13","guid":{"rendered":"https:\/\/ppr-antibioresistance.inserm.fr\/?p=26565"},"modified":"2022-10-26T10:23:40","modified_gmt":"2022-10-26T09:23:40","slug":"commission-sf2h","status":"publish","type":"post","link":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/commission-sf2h\/","title":{"rendered":"Commission SF2H : Les indicateurs des programmes de pr\u00e9vention et contr\u00f4le des infections (PCI) dans le secteur m\u00e9dico-social \u2013 R\u00e9ponse SF2H \u00e0 la saisine"},"content":{"rendered":"\n<h1 class=\"wp-block-heading\"><\/h1>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-full is-resized\"><img fetchpriority=\"high\" decoding=\"async\" src=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/10\/image-2.png\" alt=\"\" class=\"wp-image-26567\" width=\"218\" height=\"256\" srcset=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/10\/image-2.png 314w, https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/10\/image-2-255x300.png 255w\" sizes=\"(max-width: 218px) 100vw, 218px\" \/><\/figure><\/div>\n\n\n<p>\u00a0La SF2H a publi\u00e9\u00a0<a href=\"https:\/\/www.sf2h.net\/publications\/indicateurs_pci_ems\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>sa r\u00e9ponse \u00e0 la saisine<\/strong><\/a><strong>\u00a0concernant les indicateurs des programmes de pr\u00e9vention et contr\u00f4le des infections (PCI)<\/strong>\u00a0dans le secteur m\u00e9dico-social. <\/p>\n\n\n\n<p>Le document concerne les donn\u00e9es d\u2019impact des activit\u00e9s Equipes Op\u00e9rationnelles d\u2019Hygi\u00e8ne (EOH) \/ Equipes Mobiles d\u2019Hygi\u00e8ne (EMH) sur le territoire national et des indicateurs pour l\u2019\u00e9valuation de la mise en place et de l\u2019impact des programmes de\u00a0Pr\u00e9vention et Contr\u00f4le des infections (PCI)\u00a0dans le secteur ESMS.<\/p>\n\n\n\n<div style=\"height:41px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><a href=\"https:\/\/www.sf2h.net\/wp-content\/uploads\/2022\/07\/Groupe-SF2H-EMH-Indicateurs-Vdef.pdf\">Le document est disponible ici.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u00a0La SF2H a publi\u00e9\u00a0sa r\u00e9ponse \u00e0 la saisine\u00a0concernant les indicateurs des programmes de pr\u00e9vention et contr\u00f4le des infections (PCI)\u00a0dans le secteur m\u00e9dico-social. Le document concerne les donn\u00e9es d\u2019impact des activit\u00e9s Equipes Op\u00e9rationnelles d\u2019Hygi\u00e8ne (EOH) \/ Equipes Mobiles d\u2019Hygi\u00e8ne (EMH) sur le territoire national et des indicateurs pour l\u2019\u00e9valuation de la mise en place et de [&hellip;]<\/p>\n","protected":false},"author":271,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[31],"tags":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Commission SF2H : Les indicateurs des programmes de pr\u00e9vention et contr\u00f4le des infections (PCI) dans le secteur m\u00e9dico-social \u2013 R\u00e9ponse SF2H \u00e0 la saisine - French\u00a0National ANTIBIOTIC RESISTANCE Portal<\/title>\n<meta name=\"description\" content=\"Ce document correspond \u00e0 la deuxi\u00e8me partie de la r\u00e9ponse de la SF2H \u00e0 la saisine D 21-007596 \u2013 Saisine de la Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Hygi\u00e8ne Hospitali\u00e8re concernant les points suivants :\u2013 Point 4 : Donn\u00e9es d\u2019impact des activit\u00e9s EOH\/EMH sur le territoire national\u2013 Point 5 : Des indicateurs pour l\u2019\u00e9valuation de la mise en place et de l\u2019impact des programmes de PCI dans le secteur ESMS.Le point 3, \u00c9tat des lieux estimant les ETP existants sur l\u2019ensemble du territoire national pour les EOH etEMH, fait l\u2019objet d\u2019un autre rapport de la SF2H publi\u00e9 en d\u00e9cembre 2021 (V2 f\u00e9vrier 2022).Les autres points et ceux de la saisine compl\u00e9mentaire n\u00b0 D.21-007596 du 25 mars 2021 D21-007596_Complement saisine SF2H sont en cours de travail\/r\u00e9daction au sein de la SF2H.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/commission-sf2h\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Commission SF2H : Les indicateurs des programmes de pr\u00e9vention et contr\u00f4le des infections (PCI) dans le secteur m\u00e9dico-social \u2013 R\u00e9ponse SF2H \u00e0 la saisine - French\u00a0National ANTIBIOTIC RESISTANCE Portal\" \/>\n<meta property=\"og:description\" content=\"Ce document correspond \u00e0 la deuxi\u00e8me partie de la r\u00e9ponse de la SF2H \u00e0 la saisine D 21-007596 \u2013 Saisine de la Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Hygi\u00e8ne Hospitali\u00e8re concernant les points suivants :\u2013 Point 4 : Donn\u00e9es d\u2019impact des activit\u00e9s EOH\/EMH sur le territoire national\u2013 Point 5 : Des indicateurs pour l\u2019\u00e9valuation de la mise en place et de l\u2019impact des programmes de PCI dans le secteur ESMS.Le point 3, \u00c9tat des lieux estimant les ETP existants sur l\u2019ensemble du territoire national pour les EOH etEMH, fait l\u2019objet d\u2019un autre rapport de la SF2H publi\u00e9 en d\u00e9cembre 2021 (V2 f\u00e9vrier 2022).Les autres points et ceux de la saisine compl\u00e9mentaire n\u00b0 D.21-007596 du 25 mars 2021 D21-007596_Complement saisine SF2H sont en cours de travail\/r\u00e9daction au sein de la SF2H.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/commission-sf2h\/\" \/>\n<meta property=\"og:site_name\" content=\"French\u00a0National ANTIBIOTIC RESISTANCE Portal\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-26T09:20:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-10-26T09:23:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/10\/image-2.png\" \/>\n<meta name=\"author\" content=\"Loane Serrano\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Loane Serrano\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/commission-sf2h\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/commission-sf2h\/\"},\"author\":{\"name\":\"Loane Serrano\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/7993978f184ff491165415f02259de61\"},\"headline\":\"Commission SF2H : Les indicateurs des programmes de pr\u00e9vention et contr\u00f4le des infections (PCI) dans le secteur m\u00e9dico-social \u2013 R\u00e9ponse SF2H \u00e0 la saisine\",\"datePublished\":\"2022-10-26T09:20:13+00:00\",\"dateModified\":\"2022-10-26T09:23:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/commission-sf2h\/\"},\"wordCount\":119,\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/commission-sf2h\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/10\/image-2.png\",\"articleSection\":[\"Actualit\u00e9s\"],\"inLanguage\":\"en-GB\"},{\"@type\":[\"WebPage\",\"ItemPage\"],\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/commission-sf2h\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/commission-sf2h\/\",\"name\":\"Commission SF2H : Les indicateurs des programmes de pr\u00e9vention et contr\u00f4le des infections (PCI) dans le secteur m\u00e9dico-social \u2013 R\u00e9ponse SF2H \u00e0 la saisine - French\u00a0National ANTIBIOTIC RESISTANCE Portal\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/commission-sf2h\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/commission-sf2h\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/10\/image-2.png\",\"datePublished\":\"2022-10-26T09:20:13+00:00\",\"dateModified\":\"2022-10-26T09:23:40+00:00\",\"description\":\"Ce document correspond \u00e0 la deuxi\u00e8me partie de la r\u00e9ponse de la SF2H \u00e0 la saisine D 21-007596 \u2013 Saisine de la Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Hygi\u00e8ne Hospitali\u00e8re concernant les points suivants :\u2013 Point 4 : Donn\u00e9es d\u2019impact des activit\u00e9s EOH\/EMH sur le territoire national\u2013 Point 5 : Des indicateurs pour l\u2019\u00e9valuation de la mise en place et de l\u2019impact des programmes de PCI dans le secteur ESMS.Le point 3, \u00c9tat des lieux estimant les ETP existants sur l\u2019ensemble du territoire national pour les EOH etEMH, fait l\u2019objet d\u2019un autre rapport de la SF2H publi\u00e9 en d\u00e9cembre 2021 (V2 f\u00e9vrier 2022).Les autres points et ceux de la saisine compl\u00e9mentaire n\u00b0 D.21-007596 du 25 mars 2021 D21-007596_Complement saisine SF2H sont en cours de travail\/r\u00e9daction au sein de la SF2H.\",\"breadcrumb\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/commission-sf2h\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/commission-sf2h\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/commission-sf2h\/#primaryimage\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/10\/image-2.png\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/10\/image-2.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/commission-sf2h\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Practical info &amp; communications\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"News\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Commission SF2H : Les indicateurs des programmes de pr\u00e9vention et contr\u00f4le des infections (PCI) dans le secteur m\u00e9dico-social \u2013 R\u00e9ponse SF2H \u00e0 la saisine\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\",\"name\":\"French\u00a0National ANTIBIOTIC RESISTANCE Portal\",\"description\":\"INSERM - From science to health\",\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\",\"name\":\"Inserm\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"width\":1,\"height\":1,\"caption\":\"Inserm\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/7993978f184ff491165415f02259de61\",\"name\":\"Loane Serrano\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Commission SF2H : Les indicateurs des programmes de pr\u00e9vention et contr\u00f4le des infections (PCI) dans le secteur m\u00e9dico-social \u2013 R\u00e9ponse SF2H \u00e0 la saisine - French\u00a0National ANTIBIOTIC RESISTANCE Portal","description":"Ce document correspond \u00e0 la deuxi\u00e8me partie de la r\u00e9ponse de la SF2H \u00e0 la saisine D 21-007596 \u2013 Saisine de la Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Hygi\u00e8ne Hospitali\u00e8re concernant les points suivants :\u2013 Point 4 : Donn\u00e9es d\u2019impact des activit\u00e9s EOH\/EMH sur le territoire national\u2013 Point 5 : Des indicateurs pour l\u2019\u00e9valuation de la mise en place et de l\u2019impact des programmes de PCI dans le secteur ESMS.Le point 3, \u00c9tat des lieux estimant les ETP existants sur l\u2019ensemble du territoire national pour les EOH etEMH, fait l\u2019objet d\u2019un autre rapport de la SF2H publi\u00e9 en d\u00e9cembre 2021 (V2 f\u00e9vrier 2022).Les autres points et ceux de la saisine compl\u00e9mentaire n\u00b0 D.21-007596 du 25 mars 2021 D21-007596_Complement saisine SF2H sont en cours de travail\/r\u00e9daction au sein de la SF2H.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/commission-sf2h\/","og_locale":"en_GB","og_type":"article","og_title":"Commission SF2H : Les indicateurs des programmes de pr\u00e9vention et contr\u00f4le des infections (PCI) dans le secteur m\u00e9dico-social \u2013 R\u00e9ponse SF2H \u00e0 la saisine - French\u00a0National ANTIBIOTIC RESISTANCE Portal","og_description":"Ce document correspond \u00e0 la deuxi\u00e8me partie de la r\u00e9ponse de la SF2H \u00e0 la saisine D 21-007596 \u2013 Saisine de la Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Hygi\u00e8ne Hospitali\u00e8re concernant les points suivants :\u2013 Point 4 : Donn\u00e9es d\u2019impact des activit\u00e9s EOH\/EMH sur le territoire national\u2013 Point 5 : Des indicateurs pour l\u2019\u00e9valuation de la mise en place et de l\u2019impact des programmes de PCI dans le secteur ESMS.Le point 3, \u00c9tat des lieux estimant les ETP existants sur l\u2019ensemble du territoire national pour les EOH etEMH, fait l\u2019objet d\u2019un autre rapport de la SF2H publi\u00e9 en d\u00e9cembre 2021 (V2 f\u00e9vrier 2022).Les autres points et ceux de la saisine compl\u00e9mentaire n\u00b0 D.21-007596 du 25 mars 2021 D21-007596_Complement saisine SF2H sont en cours de travail\/r\u00e9daction au sein de la SF2H.","og_url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/commission-sf2h\/","og_site_name":"French\u00a0National ANTIBIOTIC RESISTANCE Portal","article_published_time":"2022-10-26T09:20:13+00:00","article_modified_time":"2022-10-26T09:23:40+00:00","og_image":[{"url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/10\/image-2.png"}],"author":"Loane Serrano","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Loane Serrano","Estimated reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/commission-sf2h\/#article","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/commission-sf2h\/"},"author":{"name":"Loane Serrano","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/7993978f184ff491165415f02259de61"},"headline":"Commission SF2H : Les indicateurs des programmes de pr\u00e9vention et contr\u00f4le des infections (PCI) dans le secteur m\u00e9dico-social \u2013 R\u00e9ponse SF2H \u00e0 la saisine","datePublished":"2022-10-26T09:20:13+00:00","dateModified":"2022-10-26T09:23:40+00:00","mainEntityOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/commission-sf2h\/"},"wordCount":119,"publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/commission-sf2h\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/10\/image-2.png","articleSection":["Actualit\u00e9s"],"inLanguage":"en-GB"},{"@type":["WebPage","ItemPage"],"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/commission-sf2h\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/commission-sf2h\/","name":"Commission SF2H : Les indicateurs des programmes de pr\u00e9vention et contr\u00f4le des infections (PCI) dans le secteur m\u00e9dico-social \u2013 R\u00e9ponse SF2H \u00e0 la saisine - French\u00a0National ANTIBIOTIC RESISTANCE Portal","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/commission-sf2h\/#primaryimage"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/commission-sf2h\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/10\/image-2.png","datePublished":"2022-10-26T09:20:13+00:00","dateModified":"2022-10-26T09:23:40+00:00","description":"Ce document correspond \u00e0 la deuxi\u00e8me partie de la r\u00e9ponse de la SF2H \u00e0 la saisine D 21-007596 \u2013 Saisine de la Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Hygi\u00e8ne Hospitali\u00e8re concernant les points suivants :\u2013 Point 4 : Donn\u00e9es d\u2019impact des activit\u00e9s EOH\/EMH sur le territoire national\u2013 Point 5 : Des indicateurs pour l\u2019\u00e9valuation de la mise en place et de l\u2019impact des programmes de PCI dans le secteur ESMS.Le point 3, \u00c9tat des lieux estimant les ETP existants sur l\u2019ensemble du territoire national pour les EOH etEMH, fait l\u2019objet d\u2019un autre rapport de la SF2H publi\u00e9 en d\u00e9cembre 2021 (V2 f\u00e9vrier 2022).Les autres points et ceux de la saisine compl\u00e9mentaire n\u00b0 D.21-007596 du 25 mars 2021 D21-007596_Complement saisine SF2H sont en cours de travail\/r\u00e9daction au sein de la SF2H.","breadcrumb":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/commission-sf2h\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/commission-sf2h\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/commission-sf2h\/#primaryimage","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/10\/image-2.png","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/10\/image-2.png"},{"@type":"BreadcrumbList","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/commission-sf2h\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Practical info &amp; communications","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/"},{"@type":"ListItem","position":3,"name":"News","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/"},{"@type":"ListItem","position":4,"name":"Commission SF2H : Les indicateurs des programmes de pr\u00e9vention et contr\u00f4le des infections (PCI) dans le secteur m\u00e9dico-social \u2013 R\u00e9ponse SF2H \u00e0 la saisine"}]},{"@type":"WebSite","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/","name":"French\u00a0National ANTIBIOTIC RESISTANCE Portal","description":"INSERM - From science to health","publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization","name":"Inserm","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","width":1,"height":1,"caption":"Inserm"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/7993978f184ff491165415f02259de61","name":"Loane Serrano"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-10 19:16:51","action":"change-status","newStatus":"private","terms":[],"taxonomy":"category"},"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/26565"}],"collection":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/users\/271"}],"replies":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/comments?post=26565"}],"version-history":[{"count":4,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/26565\/revisions"}],"predecessor-version":[{"id":26579,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/26565\/revisions\/26579"}],"wp:attachment":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/media?parent=26565"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/categories?post=26565"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/tags?post=26565"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}